TY - JOUR
T1 - 67/68Galmydar
T2 - A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity
AU - Sivapackiam, Jothilingam
AU - Harpstrite, Scott E.
AU - Prior, Julie L.
AU - Mattingly, Stephen
AU - Sharma, Vijay
N1 - Funding Information:
Authors thank Prof. David Piwnica-Worms (MD Anderson, University of Texas, Houston, TX) for helpful discussions. Financial assistance to this work was provided by grants from the National Institutes of Health in part by RO1 HL111163 (VS), R33 AG033328 (VS), CA94056 (PI: Achilefu); and P50AG05681 (PI: Morris, Pilot: VS). Finally, we thank Dr. Richard Laforest for his assistance in analysis of the PET data and Washington University Small Animal Imaging facility staff for microPET studies.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Introduction: For stratification of chemotherapeutic choices, radiopharmaceuticals capable of imaging breast cancer resistance protein (BCRP/ABCG2)-mediated functional transport are desired. To accomplish this objective, Galmydar, a fluorescent and moderately hydrophobic Ga(III) cationic complex and its 67/68Ga-radiolabeled counterparts were interrogated in HEK293 cells stably transfected with BCRP and their WT counterparts transfected with empty vector. Additionally, the sensitivity and specificity of 68Ga-Galmydar to evaluate functional expression of BCRP at the blood-brain barrier (BBB) was investigated in gene-knockout mdr1a/1b(-/-) (double knockout, dKO) and mdr1a/1b(-/-)ABCG2(-/-) (triple knockout, tKO) mouse models. Methods: For radiotracer uptake assays and live cell fluorescence imaging, either 67Ga-Galmydar or its unlabeled counterpart was incubated in HEK293 cells transfected with BCRP (HEK293/BCRP) and their WT counterparts at 37 °C under a continuous flux of CO2 (5%) in the presence or absence of Ko143, a potent BCRP antagonist, and cellular uptake was measured to assess the sensitivity of Galmydar to probe BCRP-mediated functional transport activity in cellulo. For assessing the potential of Galmydar to enable diagnostic imaging of targeted tissues in vivo, the 67Ga-radiolabeled counterpart was incubated in either human serum albumin or human serum at 37 °C and the percentage of unbound 67Ga-Galmydar was determined. To evaluate the sensitivity of 68Ga-Galmydar for molecular imaging of BCRP-mediated efflux activity in vivo, microPET/CT brain imaging was performed in dKO and tKO mice and their age-matched WT counterparts, 60 min post-intravenous injection. Results: 67Ga-Galmydar shows uptake profiles in HEK293 cells inversely proportional to BCRP expression, and antagonist (Ko143) induced accumulation in HEK293/BCRP cells, thus indicating target sensitivity and specificity. Furthermore, employing the fluorescent characteristics of Galmydar, optical imaging in HEK293/BCRP cells shows an excellent correlation with the radiotracer cellular accumulation data. 67Ga-Galmydar shows > 85% unbound fraction and presence of parental compound in human serum. Finally, microPET/CT imaging shows higher retention of 68Ga-Galmydar in brains of dKO and tKO mice compared to their age-matched WT counterparts, 60 min post-intravenous tail-vein injection. Conclusions: Combined data indicate that Galmydar could provide a template scaffold for development of a PET tracer for imaging BCRP-mediated functional transport activity in vivo.
AB - Introduction: For stratification of chemotherapeutic choices, radiopharmaceuticals capable of imaging breast cancer resistance protein (BCRP/ABCG2)-mediated functional transport are desired. To accomplish this objective, Galmydar, a fluorescent and moderately hydrophobic Ga(III) cationic complex and its 67/68Ga-radiolabeled counterparts were interrogated in HEK293 cells stably transfected with BCRP and their WT counterparts transfected with empty vector. Additionally, the sensitivity and specificity of 68Ga-Galmydar to evaluate functional expression of BCRP at the blood-brain barrier (BBB) was investigated in gene-knockout mdr1a/1b(-/-) (double knockout, dKO) and mdr1a/1b(-/-)ABCG2(-/-) (triple knockout, tKO) mouse models. Methods: For radiotracer uptake assays and live cell fluorescence imaging, either 67Ga-Galmydar or its unlabeled counterpart was incubated in HEK293 cells transfected with BCRP (HEK293/BCRP) and their WT counterparts at 37 °C under a continuous flux of CO2 (5%) in the presence or absence of Ko143, a potent BCRP antagonist, and cellular uptake was measured to assess the sensitivity of Galmydar to probe BCRP-mediated functional transport activity in cellulo. For assessing the potential of Galmydar to enable diagnostic imaging of targeted tissues in vivo, the 67Ga-radiolabeled counterpart was incubated in either human serum albumin or human serum at 37 °C and the percentage of unbound 67Ga-Galmydar was determined. To evaluate the sensitivity of 68Ga-Galmydar for molecular imaging of BCRP-mediated efflux activity in vivo, microPET/CT brain imaging was performed in dKO and tKO mice and their age-matched WT counterparts, 60 min post-intravenous injection. Results: 67Ga-Galmydar shows uptake profiles in HEK293 cells inversely proportional to BCRP expression, and antagonist (Ko143) induced accumulation in HEK293/BCRP cells, thus indicating target sensitivity and specificity. Furthermore, employing the fluorescent characteristics of Galmydar, optical imaging in HEK293/BCRP cells shows an excellent correlation with the radiotracer cellular accumulation data. 67Ga-Galmydar shows > 85% unbound fraction and presence of parental compound in human serum. Finally, microPET/CT imaging shows higher retention of 68Ga-Galmydar in brains of dKO and tKO mice compared to their age-matched WT counterparts, 60 min post-intravenous tail-vein injection. Conclusions: Combined data indicate that Galmydar could provide a template scaffold for development of a PET tracer for imaging BCRP-mediated functional transport activity in vivo.
KW - BCRP
KW - Gallium
KW - Metalloprobe
UR - http://www.scopus.com/inward/record.url?scp=84975677600&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2015.12.001
DO - 10.1016/j.nucmedbio.2015.12.001
M3 - Article
C2 - 26924499
AN - SCOPUS:84975677600
SN - 0969-8051
VL - 43
SP - 191
EP - 197
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 3
ER -